Patient characteristics
| . | Galectinlo . | Galectinhi . |
|---|---|---|
| Total (sex) | 32 (18 female:14 male) | 15 (3 female:12 male) |
| Mean age at diagnosis | 29 years (SE 1.9) | 38 years (SE 4.0) |
| Advanced clinical stage* | 11/30 (37%) | 10/15 (67%) |
| Histology† | ||
| Nodular sclerosing | 22/32 (69%) | 11/15 (73%) |
| Mixed cellularity | 4/32 (13%) | 2/15 (13%) |
| Lymphocyte-rich | 1/32 (3%) | 1/15 (7%) |
| Nodular lymphocyte-predominant | 5 (16%) | 0 (0%) |
| Hodgkin's unclassified | 0 (0%) | 1/15 (7%) |
| Positive EBV serology‡ | 31/31 (100%) | 15/15 (100%) |
| Positive EBV tissue status | 12/32 (38%) | 7/15 (47%) |
| . | Galectinlo . | Galectinhi . |
|---|---|---|
| Total (sex) | 32 (18 female:14 male) | 15 (3 female:12 male) |
| Mean age at diagnosis | 29 years (SE 1.9) | 38 years (SE 4.0) |
| Advanced clinical stage* | 11/30 (37%) | 10/15 (67%) |
| Histology† | ||
| Nodular sclerosing | 22/32 (69%) | 11/15 (73%) |
| Mixed cellularity | 4/32 (13%) | 2/15 (13%) |
| Lymphocyte-rich | 1/32 (3%) | 1/15 (7%) |
| Nodular lymphocyte-predominant | 5 (16%) | 0 (0%) |
| Hodgkin's unclassified | 0 (0%) | 1/15 (7%) |
| Positive EBV serology‡ | 31/31 (100%) | 15/15 (100%) |
| Positive EBV tissue status | 12/32 (38%) | 7/15 (47%) |
No significant differences observed between galectin-1lo and galectin-1hi cases except for sex (P = .016) and age (P = .019).
Advanced clinical stage defined as Ann Arbor (with Cotswold modification) stages IIB, III, or IV. Clinical stage was not available in 2 galectin-1lo cases.
All 5 cases of nodular lymphocyte predominant Hodgkin lymphoma scored negative for galactin-1.
Serology undetermined in one galectin-1lo case.